Publicacions en col·laboració amb investigadors/es de German Cancer Research Center (85)

2024

  1. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1

    EMBO molecular medicine, Vol. 16, Núm. 1, pp. 112-131

  2. Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission

    Rheumatology (United Kingdom), Vol. 63, Núm. 9, pp. 2473-2483

  3. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

    Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737

2023

  1. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: results from the EPIC cohort study

    BMC Medicine, Vol. 21, Núm. 1

  2. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

    Cancers, Vol. 15, Núm. 13

  3. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

  4. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial

    JAMA Oncology, Vol. 9, Núm. 12, pp. 1688-1695

  5. The Cell Tracking Challenge: 10 years of objective benchmarking

    Nature Methods, Vol. 20, Núm. 7, pp. 1010-1020

  6. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus

    eClinicalMedicine, Vol. 61

2022

  1. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells

    Cell Metabolism, Vol. 34, Núm. 6, pp. 857-873.e9

  2. Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma

    Liver International, Vol. 42, Núm. 12, pp. 2855-2870

  3. Current practice in proton therapy delivery in adult cancer patients across Europe

    Radiotherapy and Oncology, Vol. 167, pp. 7-13

  4. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

  5. Mutant IDH Inhibits IFNg–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma

    Cancer Discovery, Vol. 12, Núm. 3, pp. 812-835

  6. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

    Clinical Cancer Research, Vol. 28, Núm. 12, pp. 2555-2566

  7. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

    ESMO Open, Vol. 7, Núm. 2

  8. The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells

    Leukemia, Vol. 36, Núm. 8, pp. 1969-1979

  9. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

2021

  1. Activation-induced deaminase is critical for the establishment of DNA methylation patterns prior to the germinal center reaction

    Nucleic Acids Research, Vol. 49, Núm. 9, pp. 5057-5073

  2. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820